Skip to main content
OpenTrials
Completed

NCT Number: NCT07422259

Tolerability and Efficacy Study of Reinnerva/Lubristil+G vs Vismed

The clinical investigation #1122 is a Post Market Clinical Follow Up Study on the EC marked medical device Reinnerva/Lubristil +G, sterile eye drops, compared to Vismed medical device, sterile eye drops, to demonstrate the clinical performance and tolerability of Reinnerva/Lubristil +G to stabilize the lacrimal film and improve the ocular surface condition in the cases of quali-quantitative alterations of the tear film .

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Keratoconjunctivitis Sicca Conjunctival Diseases Conjunctivitis Corneal Diseases Dry Eye Syndromes Eye Diseases Keratitis Keratoconjunctivitis Lacrimal Apparatus Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UOC of Ophthalmology, AOU Policlinico "G. Martino"

Messina, 98125, Italy

About this study

The study aim was to demonstrate a significant improvement of the ocular surface condition with the use of Reinnerva/Lubristil +G that, based on its formulation: hydrates, stabilizes and protects the ocular surface in all cases of sensations of dryness, burning and ocular fatigue due to qualitative and quantitative alteration of the tear film.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent
  • Male and female, aged 18 to 80 years
  • Alteration of the tear film or bilateral ocular surface discomfort resulting from one of the following conditions:

Patients receiving chronic therapy with antihypertensive eye drops; Patients receiving post-ocular surgery therapy for at least 15 days

  • At least two of the following symptoms of dry eye: burning, stinging, dry eye sensation, foreign body sensation, photophobia
  • At least two of the following:

Schirmer's test (8 mm lower in 5 minutes) BUT (Burning Time) less than 10 seconds Fluorescein Infection Infection (NEI) score ≥3

Exclusion criteria

  • Active keratitis caused by herpes simplex, vaccinia virus, varicella-zoster, and other viral infections of the cornea and conjunctiva
  • Current bacterial, fungal, and tuberculosis infections
  • Corneal stromal perforations and ulcers
  • Hypersensitivity to any of the product components
  • Current ocular allergy or allergic rhinitis
  • Participation in a clinical trial in the month prior to the start of the study
  • Systemic anti-acne therapy in the 6 months prior to the start of the study
  • Any change in systemic therapy in the month prior to the start of the study
  • Contact lens use in the week prior to the start of the study

Treatment and study plan

Reinnerva/Lubristil +G sterile eye drops (artificial tears)

Device

2 drops instilled in 1 eye, 2 times daily, for 60 days

Vismed sterile eye drops (artificial tears)

Device

2 drops instilled in 1 eye, 4 times daily, for 60 days

Primary outcomes

  1. Clinical Performance and Benefit

    Time frame: From enrollment to the end of treatment at 30 and 60 days.

    Demonstrate the ability of Reinnerva/Lubristil + G to significantly improve the condition of the ocular surface assessed through subjective symptomatology expressed according to SANDE.

    The efficacy analysis has been evaluated by:

    • Change in symptoms measured by a questionnaire (SANDE - Symptom Assessment in Dry Eye) to assess patient well-being.

    Unit of Measure: The SANDE is based on a visual analog scale (VAS). The patient answers only two questions regarding the frequency and severity of symptoms. For each question, a 100-millimeter horizontal line is provided: Symptom Frequency: From "Rarely" (0 mm) to "All the Time" (100 mm). Symptom Severity: From "Very Mild" (0 mm) to "Very Severe" (100 mm).

    The final measurement (Final Score) is a numerical value between 0 and 100. The total score is obtained by calculating the square root of the product of the two scales.

    Parameters have been evaluated at the following times: T0 - screening, T30 - day 30 ± 3 days, T60 - day 60 ± 3 days

  2. Clinical Performance and Benefit

    Time frame: From enrollment to the end of treatment at 30 and 60 days.

    Demonstrate the ability of Reinnerva/Lubristil + G to significantly improve the condition of the ocular surface assessed through the Schirmer test.

    The efficacy analysis has been evaluated by:

    • Schirmer test I (without anesthesia)- quantitative parameter

    Unit of Measure: The Schirmer test measures tear production in millimeters (mm) of strip wetting over a set time, typically 5 minutes. Results indicate the length of the moisture strip, with ≤ 5 mm in 5 minutes indicating severe dry eye, while >15 mm is considered normal.

    Parameters have been evaluated at the following times: T0 - screening, T30 - day 30 ± 3 days, T60 - day 60 ± 3 days.

  3. Clinical Performance and Benefit

    Time frame: From enrollment to the end of treatment at 30 and 60 days.

    Demonstrate the ability of Reinnerva/Lubristil + G to significantly improve the condition of the ocular surface assessed through the NIK-BUT and BUT.

    The efficacy analysis has been evaluated by:

    Non-Invasive Keratograph Break-Up Time (NIKBUT)and BUT, objective, automated metric used in eye care to assess tear film stability.

    Unit of measure of NIKBUT: seconds (s). Normal tear film stability usually results in longer NIKBUT values, often exceeding 10 seconds, while dry eye conditions typically present with shorter, faster break-up times.

    Unit of measure of BUT: seconds (s). Normal result typically greater than 10 seconds, while values below 10 seconds (or especially under 5 seconds) indicate unstable, evaporative dry eye.

    Parameters have been evaluated at the following times: T0 - screening, T30 - day 30 ± 3 days, T60 - day 60 ± 3 days.

  4. Clinical Performance and Benefit

    Time frame: From enrollment to the end of treatment at 30 and 60 days.

    Demonstrate the ability of Reinnerva/Lubristil + G to significantly improve the condition of the ocular surface assessed through Tear meniscus thickness by keratography.

    The efficacy analysis has been evaluated by:

    • Tear meniscus thickness by keratograph- quantitative parameter

    Unit of Measure: Tear meniscus height (TMH) measured by the Oculus Keratograph 5M (K5M) is reported in millimeters (mm), with normal values typically ranging between 0.2 mm and 0.4 mm.

    Parameters have been evaluated at the following times: T0 - screening, T30 - day 30 ± 3 days, T60 - day 60 ± 3 days.

  5. Clinical Performance and Benefit

    Time frame: From enrollment to the end of treatment at 30 and 60 days.

    Demonstrate the ability of Reinnerva/Lubristil + G to significantly improve the condition of the ocular surface assessed through fluorescein staining and its change between baseline and after 1-2 months of treatment .

    The efficacy analysis has been evaluated by:

    • Fluorescein staining (NEI scheme - National Eye Institute Industry Workshop)/Corneal/Conjunctival evaluation with fluorescein - ordinal parameter.

    Unit of Measure: Subjective, graded scoring systems to assess corneal epithelial damage. The most common unit of measure is the NEI (National Eye Institute) Scale, a 0 to 3 scale for each of the five corneal regions (central, superior, inferior, nasal, temporal), with 0 = no stain and 3 = severe staining in each of 5 areas, based on staining density and location, totaling 0-15 point scale.

    Parameters have been evaluated at the following times: T0 - screening, T30 - day 30 ± 3 days, T60 - day 60 ± 3 days.

  6. Safety/Tolerability

    Time frame: From enrollment to the end of treatment at 30 and 60 days.

    Adverse Events (AEs): Information regarding any medical device (eye drops) defect or event reported by a patient or investigator has been monitored at each investigational visit.

    Safety and tolerability analyses have included the number of adverse events occurred during the study in the treatment group and the percentage of patients with at least one adverse event judged to be related to the medical device under study

Sponsors and collaborators

Lead sponsor

Medivis SRL

Industry

Collaborators

  • University of Messina

Registry information

Official study title

Tolerability and Efficacy of Reinnerva/Lubristil+G vs Vismed in the Treatment of the Ocular Surface of Patients With Quali-quantitative Alteration of Lacrimal Film of Different Origins

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Feb 19, 2026
Registry last updated
Feb 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.